DLX 105DMP
Alternative Names: DLX-105-DMPLatest Information Update: 28 Apr 2025
At a glance
- Originator Delarrivo
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (Topical)
- 01 Sep 2022 DelArrivo completes phase I trial in Plaque psoriasis in USA (Topical) (NCT04203433)
- 21 Mar 2022 Phase-I clinical trials in Plaque psoriasis in USA (Topical) (NCT04203433)